Oasmia Pharmaceutical AB (OASM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Oasmia Pharmaceutical AB (OASM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3347
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oasmia Pharmaceutical AB (Oasmia Pharmaceutical) is a pharmaceutical company that develops drugs for human and veterinary oncology. The company’s product portfolio consists of animal health products that include doxophos vet and paccal vet and human health products which include doxophos, paclical, docecal and OAS-19. Its paclical is a water-soluble formulation of paclitaxel and XR-17 is used as anti-cancer therapy for treatment of cancers such as breast cancer, lung cancer and ovarian cancer. The company develops products based on in-house research within nanotechnology and company patents. Oasmia Pharmaceutical provides services which includes organic synthesis, filling, analysis and freeze-drying, labeling and packaging. The company operates through research facility in Sweden. Oasmia Pharmaceutical is headquartered in Uppsala, Sweden.

Oasmia Pharmaceutical AB (OASM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 10
Private Equity 11
Nexttobe Acquires Additional Stake In Oasmia Pharma From Alceco International 11
Partnerships 12
Oasmia Pharma Enters into Marketing and Distribution Agreement with Hetero Drugs 12
Oasmia Pharma Enters Into Co-Marketing Agreement With Pharmasyntez For Paclical 13
Oasmia Pharma Enters Into Co-Development Agreement With Pharmasyntez 14
Equity Offering 15
Oasmia Pharma Plans to Raise up to USD25 Million in Public Offering of Securities 15
Oasmia Pharma Raises USD18.8 Million in Rights Offering of Shares 16
Oasmia Pharma Raises USD7.8 Million in Private Placement of Shares 17
Oasmia Pharma Raises USD2.2 Million in Private Placement of Shares 18
Oasmia Pharma Completes Underwriters Partial Exercise of Over-Allotment Option of Public Offering for USD10.8 Million 19
Oasmia Pharma Raises USD23.8 Million in Rights Offering of Shares 21
Oasmia Pharma Raises USD7 Million in Private Placement of Shares 23
Oasmia Pharma Completes Private Placement Of Shares For US$11 Million 24
Oasmia Pharma Completes Rights Issue Of Shares For US$19 Million 25
Debt Offering 26
Oasmia Pharma Raises USD3.1 Million in Private Placement of 8% Convertible Instruments 26
Oasmia Pharma Raises USD3.3 Million in Private Placement of Convertible Instruments 27
Oasmia Pharmaceutical AB – Key Competitors 28
Oasmia Pharmaceutical AB – Key Employees 29
Oasmia Pharmaceutical AB – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Jun 08, 2018: Oasmia Pharmaceutical Year-end report for the financial year May 1, 2017 – April 30, 2018 31
Mar 02, 2018: Oasmia Pharmaceutical: Interim report for the period May 2017 – January 2018 36
Dec 01, 2017: Oasmia Pharmaceutical Interim report for the period May – October 2017 38
Sep 01, 2017: Oasmia Pharmaceutical: Interim report for the period May – July 2017 39
Jun 08, 2017: Oasmia Pharmaceutical: Year-end report for the financial year May 1, 2016 – April 30, 2017 41
Corporate Communications 43
Oct 04, 2017: Oasmia Pharmaceutical Announces Resignation of its Chief Financial Officer 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oasmia Pharmaceutical AB, Deals By Therapy Area, 2012 to YTD 2018 8
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Oasmia Pharma Acquires Cancer Project KB9520 from Karo Pharma 10
Nexttobe Acquires Additional Stake In Oasmia Pharma From Alceco International 11
Oasmia Pharma Enters into Marketing and Distribution Agreement with Hetero Drugs 12
Oasmia Pharma Enters Into Co-Marketing Agreement With Pharmasyntez For Paclical 13
Oasmia Pharma Enters Into Co-Development Agreement With Pharmasyntez 14
Oasmia Pharma Plans to Raise up to USD25 Million in Public Offering of Securities 15
Oasmia Pharma Raises USD18.8 Million in Rights Offering of Shares 16
Oasmia Pharma Raises USD7.8 Million in Private Placement of Shares 17
Oasmia Pharma Raises USD2.2 Million in Private Placement of Shares 18
Oasmia Pharma Completes Underwriters Partial Exercise of Over-Allotment Option of Public Offering for USD10.8 Million 19
Oasmia Pharma Raises USD23.8 Million in Rights Offering of Shares 21
Oasmia Pharma Raises USD7 Million in Private Placement of Shares 23
Oasmia Pharma Completes Private Placement Of Shares For US$11 Million 24
Oasmia Pharma Completes Rights Issue Of Shares For US$19 Million 25
Oasmia Pharma Raises USD3.1 Million in Private Placement of 8% Convertible Instruments 26
Oasmia Pharma Raises USD3.3 Million in Private Placement of Convertible Instruments 27
Oasmia Pharmaceutical AB, Key Competitors 28
Oasmia Pharmaceutical AB, Key Employees 29
Oasmia Pharmaceutical AB, Subsidiaries 30

List of Figures
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oasmia Pharmaceutical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Oasmia Pharmaceutical AB (OASM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CVR Energy, Inc.:企業の戦略・SWOT・財務情報
    CVR Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary CVR Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • PhaseBio Pharmaceuticals Inc:企業のM&A・事業提携・投資動向
    PhaseBio Pharmaceuticals Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's PhaseBio Pharmaceuticals Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Science Applications International Corp:企業の戦略・SWOT・財務分析
    Science Applications International Corp - Strategy, SWOT and Corporate Finance Report Summary Science Applications International Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Trivitron Healthcare Pvt Ltd-医療機器分野:企業M&A・提携分析
    Summary Trivitron Healthcare Pvt Ltd (Trivitron) is a medical technology company that provides solutions to healthcare providers. The company’s products include radiography and c-arm systems, newborn screening, mammography, ultrasound, contrast media, breast biopsy system, bone densitometer, radiati …
  • Qurain Petrochemical Industries Co (ALQURAIN):石油・ガス:M&Aディール及び事業提携情報
    Summary Qurain Petrochemical Industries Co (QPIC), a subsidiary of Kuwait Projects Company Holding KSC is an investment holding company that invests in petrochemical industry and related sectors. The company develops business and financial solutions. It provides investment portfolio such as EQUATE, …
  • Tsumura & Co.:企業の戦略・SWOT・財務情報
    Tsumura & Co. - Strategy, SWOT and Corporate Finance Report Summary Tsumura & Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Labeyrie Fine Foods:企業の戦略・SWOT・財務分析
    Labeyrie Fine Foods - Strategy, SWOT and Corporate Finance Report Summary Labeyrie Fine Foods - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Slovenske elektrarne, a.s.-エネルギー分野:企業M&A・提携分析
    Summary Slovenske elektrarne, a.s. (Slovenske), is an electric utility company that generates, distributes and trades electricity. It also generates and markets heat and offers ancillary services to the power industry. The company generates electricity through various resources such as conventional …
  • Naspers Limited:企業の戦略・SWOT・財務分析
    Naspers Limited - Strategy, SWOT and Corporate Finance Report Summary Naspers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Solocal Group (LOCAL):企業の財務・戦略的SWOT分析
    Solocal Group (LOCAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • N4 Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary N4 Pharma Ltd (n4 Pharma), a subsidiary of N4 Pharma Plc, is a drug reformulation company. The company develops and out licensing of new versions of existing high value drugs with an unmet commercial or medical need. Its proprietary platform technology, Cocrys and Nuvac, focus on improving t …
  • Rolta India Ltd (ROLTA):企業の財務・戦略的SWOT分析
    Rolta India Ltd (ROLTA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Avingtrans Plc (AVG):企業の財務・戦略的SWOT分析
    Avingtrans Plc (AVG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • J.B. Hunt Transport Services, Inc. (JBHT):企業の財務・戦略的SWOT分析
    J.B. Hunt Transport Services, Inc. (JBHT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Siemens AG (SIE):企業の財務・戦略的SWOT分析
    Siemens AG (SIE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Yihai International Holding Ltd (1579):企業の財務・戦略的SWOT分析
    Yihai International Holding Ltd (1579) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Fortune Electric Co Ltd (1519):企業の財務・戦略的SWOT分析
    Summary Fortune Electric Co Ltd (Fortune Electric) is a power company that manufactures and markets transformers and accessories. The company provides products such as distribution transformers, power transformers, cast resin transformers and amorphous metal alloy core transformers, among others. It …
  • iBio Inc (IBIO):製薬・医療:M&Aディール及び事業提携情報
    Summary iBio Inc (iBio) is a biotechnology company that develops and manufactures plant made pharmaceutical products. The company provides products such as biotherapeutics and vaccines. It has its applications in ibiolaunch platform, which is a transformative technology for the production of monoclo …
  • Parexel International Corp:企業の戦略的SWOT分析
    Parexel International Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Sangoma Technologies Corporation (STC):企業の財務・戦略的SWOT分析
    Sangoma Technologies Corporation (STC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆